

# Newsletter March 2025

Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis



## Recruitment update

**Total recruitment to date: 4726**


OPTIMA Main - 4314 participants

OPTIMA prelim - 412 participants

UK*	3644
NOR	487
ANZ	173
THA	10

\*UK recruitment closed on 10th January 2025

## Recruitment countdown:



## Data, Data, Data...

As we move in to the follow up phase for most of the current OPTIMA participants, we want to thank all Sites for their hard work in collecting all data for their OPTIMA patients.

Form type	UK return rates	Non-UK return rates
Eligibility	95.06%	98.48%
Randomisation	94.73%	100.00%
Baseline details form	97.47%	97.19%
Baseline Biopsy & Surgery	97.00%	95.48%
Baseline Pathology Form	97.11%	94.38%
Baseline Tumour Characteristics	97.05%	94.23%
Treatment Forms	86.59%	91.37%
Follow-up	90.00%	96.41%

Please continue to complete and return your CRFs 😊 Thank you!

## OPTIMA Young – Expression of interest

We would like to establish the level of interest in the next phase of the OPTIMA trial.

The main change will be to amend the trial to recruit pre-menopausal patients only. We do not expect any other major changes. It is likely that UK Sites will be able to open to the new sub-set of patients, following the protocol amendment.

To register your interest in this study, we would be very grateful if you could complete the feasibility survey below.

[Expression of Interest Link](#)

NB: Please only complete this form once per Site. If someone from your Site has already completed this, please do not complete it a second time.



## We want to hear from you!

Recruitment to the OPTIMA trial has encountered challenges in meeting the anticipated targets set prior to the pandemic. Initially impeded due to the effects of Covid-19 on healthcare services, the resumption of face-to-face clinics did lead to an increase in recruitment rates. However, a lot of these rates still fell below the targets.

We would appreciate your help in finding out why this is the case so we can address any underlying issues, to help share lessons learned. Any information you can share with us will be really helpful.

[Survey Link](#)

**This survey should take about 3 minutes to complete.**

NB: Please only complete this form once per Site. If someone from your Site has already completed this, please do not complete it a second time.

## OPTIMA Patient Invoicing

The OPTIMA trial provides a one-off payment of **£124.42 per patient** randomised to cover various locally incurred research costs by participating trusts.

This payment may be claimed from the Sponsor (UCL) once all **baseline participant information (ie CRFs 1–6) has been received** by the OPTIMA Trial Office.

There is a guidance document within your Investigator Site File, titled: **Invoicing for OPTIMA per patient payment v2**

Please send any queries to [OPTIMA@warwick.ac.uk](mailto:OPTIMA@warwick.ac.uk)

### Top Tips:

Invoices must be addressed to University College London

Invoices must reference "OPTIMA Trial, UCL Project Code 527781"

Please include trial numbers (TNO's) of participants for whom payment is claimed.

No VAT is to be applied to invoices.

**Invoices do not require a UCL PO number .**

OPTIMA Trials Team: 02476 151057 | X: @OPTIMAstudy

E-mail: [OPTIMA@warwick.ac.uk](mailto:OPTIMA@warwick.ac.uk) | Website: [optimabreaststudy.com](http://optimabreaststudy.com)

